MinorAyurvedic herbal product, food supplement. Not registered as a medicine in the EU or Spain×Selective serotonin reuptake inhibitors (SSRIs)
Updated · Methodology
Mechanism
Escitalopram is metabolised in the liver mainly by CYP2C19 and to a lesser extent by CYP3A4 and CYP2D6. Omeprazole, a CYP2C19 inhibitor, raised escitalopram levels by about 50%, and caution is advised with CYP2C19 inhibitors (Cipralex SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). According to the same SmPC, serotonergic drugs increase the risk of serotonin syndrome (Cipralex SmPC, AEMPS, sections 4.4 and 4.5). Bacopa monnieri is an Ayurvedic herb. It is not authorised as a medicine in Spain and is sold as a food supplement. In the laboratory, bacopa extract inhibited CYP2C19, CYP2C9, CYP1A2 and CYP3A4, most strongly CYP2C19 (Ramasamy et al., 2014). In rats, a week of bacopa lowered CYP3A activity (Singh et al., 2013), and in young rats it raised brain serotonin (Charles et al., 2011). Its effect on these enzymes and on serotonin has not been studied in humans. However, a Polish review of 147 adverse reactions after herbal products were added to treatment describes one case of serotonin syndrome after bacopa was added to an SSRI or SNRI antidepressant (Woroń and Siwek, 2018).
Symptoms
Serotonin syndrome may be suspected when agitation, tremor, myoclonus and hyperthermia occur together (Cipralex SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). Nausea is a very common adverse effect of escitalopram (Cipralex SmPC, AEMPS, section 4.8). In a randomised trial in people over 55, bacopa 300 mg a day caused more frequent stools, abdominal cramps and nausea than placebo (Morgan and Stevens, 2010).
Management
The combination can be used with caution. According to the escitalopram SmPC, escitalopram is combined cautiously with serotonergic drugs and CYP2C19 inhibitors (Cipralex SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.4 and 4.5). Both of these properties of bacopa have so far been shown only in the laboratory and in animals, with one case of serotonin syndrome reported in a human (Woroń and Siwek, 2018). In the first weeks after bacopa is started, the person is watched for agitation, tremor, myoclonus and a rise in body temperature. If these appear, escitalopram and bacopa are stopped at once and symptomatic treatment is started (Cipralex SmPC, AEMPS, section 4.4). If nausea, drowsiness or other escitalopram adverse effects get worse, bacopa is stopped. With CYP2C19 inhibitors, the escitalopram SmPC allows the escitalopram dose to be reduced based on adverse effects (Cipralex SmPC, AEMPS, section 4.5).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica de Cipralex 10 mg (escitalopram) (2026)– AEMPS CIMA, nregistro 65230, revisión 03/2026, secciones 4.3 y 4.5
- Molecules: Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents (2014)– Ramasamy S, Kiew LV, Chung LY. Molecules. 2014;19(2):2588-601. PMID 24566323
- PLoS One: Evaluation of memory enhancing clinically available standardized extract of Bacopa monniera on P-glycoprotein and cytochrome P450 3A in Sprague-Dawley rats (2013)– Singh R, et al. PLoS One. 2013;8(8):e72517. PMID 24015255
- Journal of ethnopharmacology: Bacopa monniera leaf extract up-regulates tryptophan hydroxylase (TPH2) and serotonin transporter (SERT) expression: implications in memory formation (2011)– Charles PD, et al. J Ethnopharmacol. 2011;134(1):55-61. PMID 21129470
- Psychiatria polska: Unwanted effects of psychotropic drug interactions with medicinal products and diet supplements containing plant extracts (2018)– Woroń J, Siwek M. Psychiatr Pol. 2018;52(6):983-996. PMID 30659561
- Journal of alternative and complementary medicine: Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial (2010)– Morgan A, Stevens J. J Altern Complement Med. 2010;16(7):753-9. PMID 20590480